NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT) Is Up 12.0% After Raising MRD Revenue Guidance and Reporting Q2 Revenue Growth – Has the Bull Case Changed?
Adaptive Biotechnologies Corporation announced past second quarter 2025 earnings, reporting US$58.88 million in sales and a net loss of US$25.61 million, alongside an increased full-year MRD revenue guidance to between US$190 million and US$200 million.
The company achieved substantial improvements in both revenue and net loss year over year, while also narrowing its basic loss per share for the period.
We'll explore how strong quarterly revenue growth and raised MRD guidance could influence...